Publications by authors named "Justin L Ricker"

Claim this Profile
E
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Justin L Ricker

Cancer Discov· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Evelyn M McKeegan, Peter J Ansell, Gerard Davis, Sabrina Chan, Raj K Chandran, Justin L Ricker

Lung Cancer· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, Hagop Kantarjian, Martha Arellano, Justin L Ricker

Invest New Drugs· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M. Bouattour et al.
Calin Cainap, Mark D McKee, Justin L Ricker

J Clin Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Suresh S Ramalingam, Mikhail Shtivelband, Ross A Soo, Carlos H Barrios, Anatoly Makhson, Justin L Ricker

J Clin Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Calin Cainap, Shukui Qin, Wen-Tsung Huang, Ik Joo Chung, Hongming Pan, Justin L Ricker

J Clin Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Bert H O'Neil, Calin Cainap, Eric Van Cutsem, Vera Gorbunova, Christos S Karapetis, Justin L Ricker

Clin Colorectal Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Hao Xiong, Yi-Lin Chiu, Justin L Ricker, Patricia LoRusso

Cancer Chemother Pharmacol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.
Yi-Lin Chiu, Patricia Lorusso, Balakrishna Hosmane, Justin L Ricker, Walid Awni

Cancer Chemother Pharmacol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
Yi-Lin Chiu, Dawn M Carlson, Rajendra S Pradhan, Justin L Ricker

Clin Ther· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Han Chong Toh, Pei-Jer Chen, Brian I Carr, Jennifer J Knox, Sharlene Gill, Justin L Ricker

Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, Marc S Ernstoff, David J Perry, Justin L Ricker

Eur J Cancer· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Eng-Huat Tan, Glenwood D Goss, Ravi Salgia, Benjamin Besse, David R Gandara, Justin L Ricker

J Thorac Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Takashi Watanabe, Harumi Kato, Yukio Kobayashi, Satoshi Yamasaki, Yuriko Morita-Hoshi, Justin L Ricker

Cancer Sci· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Madeleine Duvic, Elise A Olsen, Debra Breneman, Theresa R Pacheco, Sareeta Parker, Justin L Ricker

Clin Lymphoma Myeloma· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Johan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, Cong Chen, Justin L Ricker

Invest New Drugs· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Zhong Chen, Justin L Ricker, Pramit S Malhotra, Liesl Nottingham, Lorena Bagain

Mol Cancer Ther· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
George R Blumenschein, Merrill S Kies, Vassiliki A Papadimitrakopoulou, Charles Lu, Ashok J Kumar, Justin L Ricker

Invest New Drugs· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Guillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, Alessandra Ferrajoli, Jorge Cortes, Justin L Ricker

Blood· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.
Clint T Allen, Justin L Ricker, Zhong Chen, Carter Van Waes

Head Neck· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Elise A Olsen, Youn H Kim, Timothy M Kuzel, Theresa R Pacheco, Francine M Foss, Justin L Ricker

J Clin Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Eric R Snyder, Justin L Ricker, Zhong Chen, Carter Van Waes

Cancer Lett· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Justin L Ricker

Blood· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
Eric H Rubin, Nancy G B Agrawal, Evan J Friedman, Pamela Scott, Kathryn E Mazina, Justin L Ricker

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Justin L Ricker, Zhong Chen, Xin Ping Yang, Victor S Pribluda, Glenn M Swartz

Clin Cancer Res· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis